Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $516.06, for a total transaction of $4,902,570.00. Following the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $167,432,054.58. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $519.34 on Thursday. The stock has a market capitalization of $22.05 billion, a P/E ratio of 19.17, a PEG ratio of 1.73 and a beta of 0.59. The business has a 50 day simple moving average of $540.37 and a two-hundred day simple moving average of $533.71. United Therapeutics Corporation has a 12 month low of $292.34 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the previous year, the business earned $6.41 earnings per share. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.65 EPS for the current fiscal year.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics reported second-quarter adjusted earnings of $7.27 per share, exceeding analyst estimates of roughly $6.82–$6.86 and rising from $6.41 a year earlier. Net income also increased, signaling stronger profitability despite softer sales. United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management highlighted the submission of two new drug applications, including ralinepag for rare pulmonary disease. Regulatory progress could expand the company’s pipeline and provide longer-term growth beyond its existing pulmonary arterial hypertension franchise. United Therapeutics Q2 Net Income Rises, Revenue Falls
• Neutral Sentiment: The earnings call and presentation gave investors additional detail on quarterly performance, pipeline development and upcoming regulatory milestones. Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target of approximately $648, above recent trading levels. United Therapeutics Corporation Q2 2026 Earnings Call Transcript
• Negative Sentiment: Second-quarter revenue declined approximately 2% year over year to $783.3 million, compared with $798.6 million a year earlier. The sales decline suggests that earnings growth was driven more by profitability and cost dynamics than by accelerating top-line demand. United Therapeutics Reports Q2 Earnings: Key Metrics
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares worth about $4.9 million, reducing her direct ownership by 2.84%. While the sale may be routine, insider selling can create a modest overhang for investor sentiment. United Therapeutics CEO SEC Filing

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Raymond James Financial began coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. boosted their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Finally, Royal Bank Of Canada upped their price target on United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $648.33.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Torren Management LLC purchased a new stake in shares of United Therapeutics during the 4th quarter valued at approximately $26,000. Activest Wealth Management lifted its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC grew its position in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. grew its position in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC acquired a new stake in United Therapeutics during the fourth quarter worth $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.